Prostate cancer risk prediction using polygenic hazard scores in Norwegian populations

Le résumé fourni par la source

Abstract More accurate risk prediction is needed for prostate cancer (PCa) to identify individuals at greatest risk of early-onset and clinically significant disease. Current screening paradigms, such as prostate-specific antigen screening, pose risks due to over-diagnosis and over-treatment of indolent disease. Polygenic hazard scores (PHS) can predict age-at-diagnosis of PCa and are being tested in prospective clinical screening trials. We assessed the performance of the latest PHS model for PCa (PHS601) in two Norwegian population-based cohort studies (N = 14,688 and N = 2,850) for predicting age-at-diagnosis of PCa and aggressive PCa. In a subset with whole-genome sequencing (N = 503), we directly compared PHS601-based stratification with screening for rare pathogenic variants. PHS601 effectively stratified participants by risk in both cohorts for both PCa (HR 80/20 = 5.74, 95% CI [5.06, 6.45] and 7.79 95% CI [5.70, 10.59]) and aggressive PCa (HR 80/20 = 4.60, 95% CI [3.19, 6.45] and 3.14 95% CI [1.49, 6.63]). Among individuals with whole-genome sequencing, the top 1.8% of PHS values conferred 8.8-fold higher risk than the median (HR = 8.78 [5.00, 14.40]), exceeding the risk associated with HOXB13 pathogenic variants (HR = 3.77 [1.75, 8.11]; 1.8% carrier frequency). This study provides the first external validation of PHS601 in independent Norwegian population-based cohorts and, within a WGS subset, a direct comparison with rare variant screening, supporting context-specific use of genotyping-based risk stratification in population screening.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.